Monitoring Report: GLP-1 RA Prescribing Trends – December 2025 Data

Background

Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.

For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.

Objective

To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.

Methods

Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2019 and December 31, 2025. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.

Results

2,185,238 patients were prescribed a GLP-1 RA between January 2019 and December 2025, with 11,194,909 total prescriptions during this period. Among first-time prescriptions for which use could be established, 69.1% were ADMs and 30.9% were AOMs. Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased slightly from September to December 2025 (+5.02%); however, first-time prescribing rates declined over the same period (-6.62%). As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions.